GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Initiator Pharma A/S (OSTO:INIT) » Definitions » Debt-to-EBITDA

Initiator Pharma A/S (OSTO:INIT) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Initiator Pharma A/S Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Initiator Pharma A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Initiator Pharma A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Initiator Pharma A/S's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-21.72 Mil. Initiator Pharma A/S's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Initiator Pharma A/S's Debt-to-EBITDA or its related term are showing as below:

OSTO:INIT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.68   Med: -0.57   Max: -0.3
Current: -0.68

During the past 8 years, the highest Debt-to-EBITDA Ratio of Initiator Pharma A/S was -0.30. The lowest was -0.68. And the median was -0.57.

OSTO:INIT's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs OSTO:INIT: -0.68

Initiator Pharma A/S Debt-to-EBITDA Historical Data

The historical data trend for Initiator Pharma A/S's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Initiator Pharma A/S Debt-to-EBITDA Chart

Initiator Pharma A/S Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - - -0.58 -0.30 -0.57

Initiator Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.36 -0.75 -0.90 -

Competitive Comparison of Initiator Pharma A/S's Debt-to-EBITDA

For the Biotechnology subindustry, Initiator Pharma A/S's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Initiator Pharma A/S's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Initiator Pharma A/S's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Initiator Pharma A/S's Debt-to-EBITDA falls into.



Initiator Pharma A/S Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Initiator Pharma A/S's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 23.168) / -40.566
=-0.57

Initiator Pharma A/S's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -21.716
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Initiator Pharma A/S  (OSTO:INIT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Initiator Pharma A/S Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Initiator Pharma A/S's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Initiator Pharma A/S (OSTO:INIT) Business Description

Traded in Other Exchanges
N/A
Address
Co/ COBIS, Ole Maaloesvej 3, Copenhagen, DNK, 2200
Initiator Pharma A/S is a clinical Stage Life Science company engaged in the research and development of various drugs targeting medical needs within the central and peripheral nervous system. The company's principal drug candidate is the IPED2015, a type of monoamine reuptake inhibitor (MRI) that has completed preclinical development for the treatment of erectile dysfunction in men. Its MRI drug candidates also include IPDP2015 for the treatment of depression; and IPNP2015 to treat neuropathic pain.

Initiator Pharma A/S (OSTO:INIT) Headlines

No Headlines